TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of $5.53 billion. The enterprise value is $5.51 billion.

Market Cap	5.53B
Enterprise Value	5.51B

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025, before market open.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

TG Therapeutics has 145.84 million shares outstanding. The number of shares has increased by 9.66% in one year.

Current Share Class	145.84M
Shares Outstanding	145.84M
Shares Change (YoY)	+9.66%
Shares Change (QoQ)	+1.58%
Owned by Insiders (%)	7.33%
Owned by Institutions (%)	71.71%
Float	135.08M

Valuation Ratios

The trailing PE ratio is 159.36 and the forward PE ratio is 32.67. TG Therapeutics's PEG ratio is 0.29.

PE Ratio	159.36
Forward PE	32.67
PS Ratio	14.28
Forward PS	8.31
PB Ratio	23.23
P/TBV Ratio	23.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	0.29

Financial Ratio History

Enterprise Valuation

EV / Earnings	140.81
EV / Sales	14.27
EV / EBITDA	92.08
EV / EBIT	92.16
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.07.

Current Ratio	4.02
Quick Ratio	2.91
Debt / Equity	1.07
Debt / EBITDA	4.10
Debt / FCF	n/a
Interest Coverage	2.10

Financial Efficiency

Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 9.79%.

Return on Equity (ROE)	19.70%
Return on Assets (ROA)	7.26%
Return on Invested Capital (ROIC)	9.79%
Return on Capital Employed (ROCE)	12.05%
Revenue Per Employee	$1.14M
Profits Per Employee	$115,828
Employee Count	338
Asset Turnover	0.75
Inventory Turnover	0.41

Taxes

In the past 12 months, TG Therapeutics has paid $2.59 million in taxes.

Income Tax	2.59M
Effective Tax Rate	6.21%

Stock Price Statistics

The stock price has increased by +97.76% in the last 52 weeks. The beta is 1.94, so TG Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.94
52-Week Price Change	+97.76%
50-Day Moving Average	37.23
200-Day Moving Average	32.37
Relative Strength Index (RSI)	56.11
Average Volume (20 Days)	1,731,949

Short Selling Information

The latest short interest is 23.58 million, so 16.17% of the outstanding shares have been sold short.

Short Interest	23.58M
Short Previous Month	22.57M
Short % of Shares Out	16.17%
Short % of Float	17.45%
Short Ratio (days to cover)	8.30

Income Statement

In the last 12 months, TG Therapeutics had revenue of $386.39 million and earned $39.15 million in profits. Earnings per share was $0.24.

Revenue	386.39M
Gross Profit	337.80M
Operating Income	59.82M
Pretax Income	n/a
Net Income	39.15M
EBITDA	59.87M
EBIT	59.82M
Earnings Per Share (EPS)	$0.24

Full Income Statement

Balance Sheet

The company has $276.24 million in cash and $254.58 million in debt, giving a net cash position of $21.66 million or $0.15 per share.

Cash & Cash Equivalents	276.24M
Total Debt	254.58M
Net Cash	21.66M
Net Cash Per Share	$0.15
Equity (Book Value)	237.29M
Book Value Per Share	1.63
Working Capital	484.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$61.03 million and capital expenditures -$70,000, giving a free cash flow of -$61.10 million.

Operating Cash Flow	-61.03M
Capital Expenditures	-70,000
Free Cash Flow	-61.10M
FCF Per Share	-$0.42

Full Cash Flow Statement

Margins

Gross margin is 87.43%, with operating and profit margins of 15.48% and 10.13%.

Gross Margin	87.43%
Operating Margin	15.48%
Pretax Margin	10.80%
Profit Margin	10.13%
EBITDA Margin	15.49%
EBIT Margin	15.48%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.66%
Shareholder Yield	-9.66%
Earnings Yield	0.71%
FCF Yield	-1.10%

Dividend Details

Analyst Forecast

The average price target for TG Therapeutics is $40.80, which is 7.51% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$40.80
Price Target Difference	7.51%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	38.14%
EPS Growth Forecast (5Y)	95.60%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on April 30, 2012. It was a reverse split with a ratio of 0.0177777:1.

Last Split Date	Apr 30, 2012
Split Type	Reverse
Split Ratio	0.0177777:1

Scores

TG Therapeutics has an Altman Z-Score of 3.66 and a Piotroski F-Score of 3.

Altman Z-Score	3.66
Piotroski F-Score	3